Novavax’s stock price soared on May 19, 2025, after the FDA announced a promising development for the company’s COVID-19 vaccine. The stock surged over 15%, marking one of its largest gains in recent times.
The FDA confirmed that a late-stage clinical trial had shown high efficacy and safety for Novavax’s COVID-19 vaccine candidate. This news has led investors to take notice, pushing the company’s shares to new heights.
Source: https://www.barrons.com/articles/novavax-stock-fda-vaccine-approval-0c9ae8be